Bionor
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn
The companies will aim to discover new antibody-based therapeutics for cancer
Cultivating Interest in Infectious Disease Education at ID Week 2024
IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...
Innovative Trials Announces New Charity Partnerships
Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year
Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations
“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...
Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership
The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...
Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate
STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio
New technique enables study of immune response to cancer using archived tissue samples
FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples